UBS Group’s Sunshine Biopharma Inc Warrant SBFMW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $546 | Sell |
11,879
-12,000
| -50% | -$908 | ﹤0.01% | 9806 |
|
|
2026
Q1 | $1.79K | Buy |
23,879
+1,396
| +6% | +$197 | ﹤0.01% | 9431 |
|
|
2025
Q4 | $2.94K | Sell |
22,483
-921
| -4% | -$213 | ﹤0.01% | 9180 |
|
|
2025
Q3 | $3.16K | Sell |
23,404
-1,165
| -5% | -$235 | ﹤0.01% | 9080 |
|
|
2025
Q2 | $5.65K | Sell |
24,569
-5,162
| -17% | -$1.33K | ﹤0.01% | 9153 |
|
|
2025
Q1 | $6.01K | Buy |
29,731
+28,442
| +2,207% | +$6.37K | ﹤0.01% | 8939 |
|
|
2024
Q4 | $208 | Sell |
1,289
-600
| -32% | -$93 | ﹤0.01% | 9567 |
|
|
2024
Q3 | $198 | Sell |
1,889
-834
| -31% | -$85 | ﹤0.01% | 9079 |
|
|
2024
Q2 | $221 | Buy |
2,723
+2,684
| +6,882% | +$264 | ﹤0.01% | 9065 |
|
|
2024
Q1 | $2 | Sell |
39
-60
| -61% | -$6 | ﹤0.01% | 9188 |
|
|
2023
Q4 | $15 | Sell |
99
-562
| -85% | -$124 | ﹤0.01% | 9094 |
|
|
2023
Q3 | $149 | Sell |
661
-82,471
| -99% | -$25.7K | ﹤0.01% | 8785 |
|
|
2023
Q2 | $31.4K | Buy |
+83,132
| New | +$37.3K | ﹤0.01% | 6694 |
|
|
2023
Q1 | – | Sell |
-400
| Closed | -$132 | – | 10274 |
|
|
2022
Q4 | $132 | Sell |
400
-9,873
| -96% | -$4.72K | ﹤0.01% | 10364 |
|
|
2022
Q3 | $4K | Sell |
10,273
-287
| -3% | -$212 | ﹤0.01% | 9388 |
|
|
2022
Q2 | $8K | Buy |
10,560
+9,948
| +1,625% | +$17.6K | ﹤0.01% | 8342 |
|
|
2022
Q1 | $1K | Buy |
+612
| New | +$427 | ﹤0.01% | 9914 |
|
Other funds holding SBFMW
UBS Group's SBFMW Position: Q2 2026 in Review
UBS Group reduced its Sunshine Biopharma Inc Warrant (SBFMW) stake by 50% in Q2 2026, selling an estimated $908 and leaving 11,879 shares worth $546. The position accounts for ﹤0.01% of the portfolio, ranked #9806.
UBS Group first reported a position in SBFMW in Q1 2022 and has held it in 17 quarters since. The position peaked at $31.4K in Q2 2023. 3 funds tracked by Wall St. Rank hold SBFMW as of Q2 2026.
- UBS Group held 11,879 shares of Sunshine Biopharma Inc Warrant worth $546 as of Q2 2026.
- UBS Group sold 12,000 Sunshine Biopharma Inc Warrant shares in Q2 2026, an estimated $908.
- Sunshine Biopharma Inc Warrant made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9806 holding.
- UBS Group first reported a position in Sunshine Biopharma Inc Warrant in Q1 2022 and has held it in 17 quarters since.
- UBS Group's Sunshine Biopharma Inc Warrant position peaked at $31.4K in Q2 2023.
- 3 funds tracked by Wall St. Rank held Sunshine Biopharma Inc Warrant as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.